Kodiak Sciences (KOD)

• Market cap: $205M
• 1 day: 5.43%
• 5 days: -8.49%
• 1 month: -3.72%
• 3 months: 12.46%
• 6 months: -54.19%
• Year to date: -54.99%
• 1 year: 40.58%
• 5 years: -93.84%
• 10 years: -61.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Employees: 113

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2,700% more call options, than puts

Call options by funds: $56K | Put options by funds: $2K

33% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 30

17% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 18

1.54% more ownership

Funds ownership: 79.92% [Q4 2024] → 81.46% (+1.54%) [Q1 2025]

0% more funds holding

Funds holding: 106 [Q4 2024] → 106 (+0) [Q1 2025]

71% less capital invested

Capital invested by funds: $418M [Q4 2024] → $120M (-$298M) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 0 (-2) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 23% downside
• Avg. target: $3 23% downside
• High target: $3 23% downside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield

23% downside $3

Neutral Reiterated

31 Mar 2025